Skip to main content

Advertisement

SpringerLink
Log in

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma is a rising cause of morbidity and mortality in the USA and around the world. Surgical resection and liver transplantation are the preferred management strategies; however, less than 30% of patients are eligible for surgery. Stereotactic body radiation therapy is a promising local treatment option for non-surgical candidates. Local control rates between 95 and 100% have been reported at 1–2 years post-treatment, and classical radiation-induced liver disease described with conventional radiation is an unlikely complication from stereotactic radiotherapy. Enrollment in randomized trials will be essential in establishing the role of stereotactic radiation in treatment paradigms for hepatocellular carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Xu J. Trends in liver cancer mortality among adults aged 25 and Over in the United States, 2000–2016. In: NCHS Data Brief, no 314. Hyattsville, MD, National Center for Health Statistics, 2018; 2018.

  3. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med. 1965;93:200–208.

    CAS  PubMed  Google Scholar 

  4. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–821.

    Article  PubMed  Google Scholar 

  5. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739–8747.

    Article  PubMed  Google Scholar 

  6. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18:2210–2218.

    Article  CAS  PubMed  Google Scholar 

  7. Boda-Heggemann J, Knopf AC, Simeonova-Chergou A, et al. Deep inspiration breath hold-based radiation therapy: a clinical review. Int J Radiat Oncol Biol Phys. 2016;94:478–492.

    Article  PubMed  Google Scholar 

  8. Giraud P, Morvan E, Claude L, et al. Respiratory gating techniques for optimization of lung cancer radiotherapy. J Thorac Oncol. 2011;6:2058–2068.

    Article  PubMed  Google Scholar 

  9. Oldrini G, Taste-George H, Renard-Oldrini S, et al. Implantation of fiducial markers in the liver for stereotactic body radiation therapy: feasibility and results. Diagn Interv Imaging. 2015;96:589–592.

    Article  CAS  PubMed  Google Scholar 

  10. Park SH, Won HJ, Kim SY, et al. Efficacy and safety of ultrasound-guided implantation of fiducial markers in the liver for stereotactic body radiation therapy. PLoS One. 2017;12:e0179676.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631–1639.

    Article  PubMed  Google Scholar 

  12. Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5:e443–e449.

    Article  PubMed  Google Scholar 

  13. Weiner AA, Olsen J, Ma D, et al. Stereotactic body radiotherapy for primary hepatic malignancies—report of a phase I/II institutional study. Radiother Oncol. 2016;121:79–85.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Feng M, Suresh K, Schipper MJ, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol. 2018;4:40–47.

    Article  PubMed  Google Scholar 

  15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.

    Article  CAS  Google Scholar 

  16. Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014;111:412–417.

    Article  PubMed  Google Scholar 

  17. Sakka SG. Assessment of liver perfusion and function by indocyanine green in the perioperative setting and in critically ill patients. J Clin Monit Comput. 2017;32(5):787–796.

    Article  PubMed  Google Scholar 

  18. Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest. 2002;122:1715–1720.

    Article  PubMed  Google Scholar 

  19. Stenmark MH, Cao Y, Wang H, et al. Estimating functional liver reserve following hepatic irradiation: adaptive normal tissue response models. Radiother Oncol. 2014;111:418–423.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:831–836.

    Article  PubMed  Google Scholar 

  21. Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer. 2011;117:3053–3059.

    Article  PubMed  Google Scholar 

  22. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34:460–468.

    Article  CAS  PubMed  Google Scholar 

  23. Kasuya G, Kato H, Yasuda S, et al. Group LCW: progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. Cancer. 2017;123:3955–3965.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34:452–459.

    Article  CAS  PubMed  Google Scholar 

  25. Sapir E, Tao Y, Schipper MJ, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122–130.

    Article  PubMed  Google Scholar 

  26. O’Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl. 2012;18:949–954.

    Article  PubMed  Google Scholar 

  27. Mannina EM, Cardenes HR, Lasley FD, et al. Role of stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes. Int J Radiat Oncol Biol Phys. 2017;97:931–938.

    Article  PubMed  Google Scholar 

  28. Mohamed M, Katz AW, Tejani MA, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 2016;1:35–42.

    Article  PubMed  Google Scholar 

  29. Sapisochin G, Barry A, Doherty M, et al. Grant DR: stereotactic body radiotherapy vs TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma: an intention-to-treat analysis. J Hepatol. 2017;67:92–99.

    Article  PubMed  Google Scholar 

  30. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?term=randomized%2C+radiation&cond=Hepatocellular+Carcinoma&Search=Apply&recrs=g&recrs=h&recrs=i&recrs=m&age_v=&gndr=&type=&rslt=. Accessed 02 Aug 2018.

  31. Habraken SJM, Sharfo AWM, Buijsen J, et al. The TRENDY multi-center randomized trial on hepatocellular carcinoma—trial QA including automated treatment planning and benchmark-case results. Radiother Oncol. 2017;125:507–513.

    Article  PubMed  Google Scholar 

  32. SBRT or TACE for Advanced HCC. https://clinicaltrials.gov/ct2/show/NCT03338647. Accessed 02 Aug 2018.

  33. Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR). https://clinicaltrials.gov/ct2/NCT02921139. Accessed 02 Aug 2018.

  34. Comparison of SBRT and Repeat TACE for HCC (STH). https://clinicaltrials.gov/ct2/show/NCT03326375. Accessed 02 Aug 2018.

  35. Transarterial chemoembolization compared with stereotactic body radiation therapy or stereotactic ablative radiation therapy in treating patients with residual or recurrent liver cancer undergone initial transarterial chemoembolization. https://clinicaltrials.gov/ct2/show/NCT02762266. Accessed 02 Aug 2018.

  36. Stereotactic body radiation therapy (SBRT) versus trans-arterial chemoembolization (TACE) as bridge to liver transplant (SBRTvsTACE). https://clinicaltrials.gov/ct2/show/NCT02182687. Accessed 02 Aug 2018.

  37. Radiotherapy versus no intervention in adult patients with hepatocellular carcinoma not eligible for transarterial chemoembolization or ablation prior to liver transplant (RADBRI). https://clinicaltrials.gov/ct2/show/NCT03172559. Accessed 02 Aug 2018.

  38. Stereotactic body radiotherapy and microwave ablation for recurrent small hepatocellular carcinoma. https://clinicaltrials.gov/ct2/show/NCT03609268. Accessed 02 Aug 2018.

  39. Trial comparing PLA to HIGRT therapy (PROVE-HCC). https://clinicaltrials.gov/ct2/show/NCT03402607. Accessed 02 Aug 2018.

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology Service, Hunter Holmes McGuire VA Medical Center, 1201 Broad Rock Blvd, Richmond, VA, 23249, USA

    Payal D. Soni

  2. Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA

    Manisha Palta

Authors
  1. Payal D. Soni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manisha Palta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Payal D. Soni.

Ethics declarations

Conflict of interest

Payal D. Soni, MD has no conflict of interest. Manisha Palta, MD has received research support from Merck and Varian. She has received honorarium from Oakstone CME and UptoDate and also received consultant fees from Navigant.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soni, P.D., Palta, M. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities. Dig Dis Sci 64, 1008–1015 (2019). https://doi.org/10.1007/s10620-019-05539-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05539-0

Keywords

Search

Navigation